The Filing Desk

BioAge Labs vs Curis

BioAge Labs BIOA · Curis CRIS · Biotechnology

Curis reported revenue of $9 million in fiscal 2025, about the same as BioAge Labs' $9 million in fiscal 2025. BioAge Labs had an operating margin of -1031.5%, against -60.5% at Curis.

Side by side

BioAge LabsCuris
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$9M$9M
Revenue growth—−13.4%
Revenue growth a year, last 5 years—−2.7%
Gross margin——
Operating margin−1,031.5%−60.5%
Net margin−896.1%−80.3%
Free cash flow−$82M—
Free cash flow margin−915.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count235.0%108.7%
Last close$4.71$0.47
P/E at the last close——
Insider trades, last 12 monthssold $7.8 millionbought $5,500, sold $0
Piotroski F-score4 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioAge LabsCuris
Operating margin
Percent of revenue
BioAge LabsCuris
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioAge LabsCuris

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioAge Labs and Curis pages.